Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Heron Therapeutics reported a quarterly loss of $0.02 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, but an improvement from a loss of $0.06 per share a year ago, indicating a surprise of -100.00% [1] - The company posted revenues of $37.2 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.89%, but showing an increase from $36.02 million in the same quarter last year [2] - Over the last four quarters, Heron Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Heron Therapeutics shares have increased approximately 20.3% since the beginning of the year, outperforming the S&P 500's gain of 7.8% [3] - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $39.28 million, while for the current fiscal year, it is -$0.02 on revenues of $158.1 million [7] Industry Outlook - The Medical - Drugs industry, to which Heron Therapeutics belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Heron Therapeutics' stock performance [5]